Proteome Systems to Ditch Rx Business, Focus on Dx

Aug 22, 2008

NEW YORK (GenomeWeb News) – Proteome Systems today said that it would shut down its drug development business and focus solely on biomarker-based diagnostics operations.

The Sydney, Australia-based firm has been trying to develop a therapeutic compound portfolio since its merger with Eukarion in 2005. However, that portfolio “no longer fits with our corporate development strategy,” the company said.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Breaking News

The Scan

NIH's Collins on Harassment

In a statement, National Institutes of Health Director Francis Collins says sexual harassment is "morally indefensible" and "unacceptable."

With Eight Arms and Giant Eyes

Octopuses might owe their intelligence to their liberal alterations to their genes, Cosmos reports.

Missing From Trials

Stat News and ProPublica report that African Americans are underrepresented in cancer clinical trials.

This Week in Cell

In Cell this week: genomic analysis of abdominal aortic aneurysm, effect of probiotics on the microbiome, and more.

Main menu